scholarly journals May a Relationship Occur Between Peripartum Cardiomyopathy and Restrictive Cardiomyopathy?

2021 ◽  
Vol 9 (4) ◽  
pp. 213-216
Author(s):  
Hatice Taşkan ◽  
Serkan Asil ◽  
Ender Murat ◽  
Selen Eşki ◽  
Hasan Kutsi Kabul
Keyword(s):  
Restrictive Cardiomyopathy ◽  
Peripartum Cardiomyopathy

640 Can echocardiography offer a coherent interpretation of various entities included in restrictive cardiomyopathy?

1999 ◽  
Vol 1 ◽  
pp. S108-S108
Author(s):  
C GINGHINA ◽  
E APETREI ◽  
I STOIAN ◽  
M MARINESCU ◽  
I KULCSAR ◽  
...  
Keyword(s):  
Restrictive Cardiomyopathy

Peripartum Cardiomyopathy Improved With Bromocriptine

2007 ◽  
Vol 5 (10) ◽  
pp. 11
Author(s):  
BRUCE JANCIN
Keyword(s):  
Peripartum Cardiomyopathy

Race Drives Path Of Peripartum Cardiomyopathy

2007 ◽  
Vol 37 (13) ◽  
pp. 11
Author(s):  
Bruce Jancin
Keyword(s):  
Peripartum Cardiomyopathy

scholarly journals Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Ryan M. Baxley ◽  
Wendy Leung ◽  
Megan M. Schmit ◽  
Jacob Peter Matson ◽  
Lulu Yin ◽  
...  
Keyword(s):  
Immune Cell ◽  
Nk Cell ◽  
Restrictive Cardiomyopathy ◽  
Telomerase Activity ◽  
Compound Heterozygous ◽  
Minichromosome Maintenance ◽  
Telomere Shortening ◽  
Clinical Phenotypes ◽  
Eukaryotic Dna ◽  
Minichromosome Maintenance Protein

AbstractMinichromosome maintenance protein 10 (MCM10) is essential for eukaryotic DNA replication. Here, we describe compound heterozygous MCM10 variants in patients with distinctive, but overlapping, clinical phenotypes: natural killer (NK) cell deficiency (NKD) and restrictive cardiomyopathy (RCM) with hypoplasia of the spleen and thymus. To understand the mechanism of MCM10-associated disease, we modeled these variants in human cell lines. MCM10 deficiency causes chronic replication stress that reduces cell viability due to increased genomic instability and telomere erosion. Our data suggest that loss of MCM10 function constrains telomerase activity by accumulating abnormal replication fork structures enriched with single-stranded DNA. Terminally-arrested replication forks in MCM10-deficient cells require endonucleolytic processing by MUS81, as MCM10:MUS81 double mutants display decreased viability and accelerated telomere shortening. We propose that these bi-allelic variants in MCM10 predispose specific cardiac and immune cell lineages to prematurely arrest during differentiation, causing the clinical phenotypes observed in both NKD and RCM patients.

scholarly journals Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM)

2021 ◽  
Author(s):  
J. Hoevelmann ◽  
E. Muller ◽  
F. Azibani ◽  
S. Kraus ◽  
J. Cirota ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Systolic Function ◽  
Point Of Care ◽  
Diagnostic Value ◽  
Left Ventricular ◽  
Peripartum Cardiomyopathy ◽  
Lv Function ◽  
Myocardial Recovery ◽  
End Diastolic Volume

Abstract Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with persistently reduced systolic function. Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide (NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and LV ejection fraction (LVEF). Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml (IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions (LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], p = 0.035) at follow-up. Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our findings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.

Sign in / Sign up

Export Citation Format

Share Document